ALNY Q3 2022 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$264M+40.9% YoY

Gross Profit

$223M84.4% margin

Operating Income

-$258M-97.6% margin

Net Income

-$406M-153.6% margin

EPS (Diluted)

$-3.32

QoQ Revenue Growth

+17.6%

Cash Flow

Operating Cash Flow

-$115M

Free Cash Flow

-$132M

Stock-Based Comp.

$128M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.6B

Stockholders' Equity

-$68M

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$264M	$188M	+40.9%
Gross Profit	$223M	$155M	+44.0%
Operating Income	-$258M	-$182M	-42.0%
Net Income	-$406M	-$205M	-98.5%

Revenue Segments

Product

$232M99%

Royalty

$3M1%

Geographic Segments

Europe

$9M57%

UNITED STATES

$6M39%

Non-US Or Europe

$698,0004%